Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI‐PDFF as the reference standard
Journal of Digestive Diseases · 2023-12 · 24 (12) · 691-701
DOI: 10.1111/1751-2980.13242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, online erschienen am 22.12.2023. Verfasst von Rong Mu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Objective
To estimate the performance of the FibroTouch‐based ultrasound attenuation parameter (UAP) for assessing hepatic steatosis in nonalcoholic fatty liver disease (NAFLD), with magnetic resonance imaging proton density fat fraction (MRI‐PDFF) as the reference standard.
Methods
This prospective, cross‐sectional study included 275 individuals in the training group and 110 individuals in the validation group, all of whom completed a standardized research visit, laboratory tests, MRI‐PDFF, and UAP measurements over 1 month. Pearson correlation coefficient and Bland–Altman analysis were used to assess the agreement between UAP and MRI‐PDFF for the detection of hepatic steatosis. The diagnostic value of UAP was evaluated by the area under the receiver operating characteristic (ROC) curve (AUROC). Confounding factors to UAP performance were identified by ROC curves and regression analyses.
Results
The AUROC of UAP for detecting MRI‐PDFF at ≥5%, ≥10%, and ≥20% were 0.95 (95% confidence interval [CI] 0.92–0.97), 0.86 (95% CI 0.81–0.90), and 0.90 (95% CI 0.86–0.93), respectively, and their optimal thresholds were 259, 274, and 295 dB/m, respectively. The UAP measurements had higher diagnostic accuracy in participants with lower waist circumference (≤90 cm for men and ≤80 cm for women) compared to those with higher waist circumference (AUROC values: 0.97 vs 0.84, P < 0.05). Bland–Altman analysis showed good agreement between UAP and MRI‐PDFF (bias 0.00021). According to established regression analyses, hepatic steatosis could be accurately diagnosed using UAP estimation.
Conclusions
FibroTouch‐UAP has a high diagnostic potential for hepatic steatosis in NAFLD patients and helps clinical assessment and monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Lun Gen Lu
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Mu, R., Xia, Y. C., Zhu, K. Y., Lu, J. Y., Luo, Q., Zhang, L., Lin, R. K., Cai, X. B., Qu, Y., & Lu, L. G. (2023). Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI‐PDFF as the reference standard. Journal of Digestive Diseases, 24(12), 691-701. https://doi.org/10.1111/1751-2980.13242
Vancouver
Mu R, Xia YC, Zhu KY, Lu JY, Luo Q, Zhang L, et al. Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI‐PDFF as the reference standard. Journal of Digestive Diseases. 2023;24(12):691-701. doi:10.1111/1751-2980.13242
BibTeX
@article{Mu2023,
author = {Mu, Rong and Xia, You Chen and Zhu, Kou Yun and Lu, Jing Yi and Luo, Qian and Zhang, Lei and Lin, Ren Kun and Cai, Xiao Bo and Qu, Ying and Lu, Lun Gen},
title = {Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI‐PDFF as the reference standard},
journal = {Journal of Digestive Diseases},
year = {2023},
volume = {24},
number = {12},
pages = {691--701},
doi = {10.1111/1751-2980.13242}
}
EUVIMED